TransPRIDE

• Research type

  Research Study

• Full title

  Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study

• IRAS ID

  336982

• Contact name

  Alison May Berner

• Contact email

  a.m.berner@qmul.ac.uk

• Sponsor organisation

  Queen Mary University of London

• Duration of Study in the UK

  2 years, 4 months, 31 days

• Research summary

  The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer.

  The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people.
  Anyone with a prostate can get prostate cancer. The prostate remains after genital (lower) surgery. The hormones and surgeries that trans women and non-binary people might have can lower the PSA. We do not have good data on the normal PSA levels are for this group

  TransPRIDE is a research study that will help us find the normal levels of PSA in trans women and non-binary people with prostates and also help us screen for prostate cancer in this population.

  Researchers will ask 500 trans women and non-binary people with prostates to take part. They will need to be aged 40 or over. They will need to be on hormones or have had genital (lower) surgery. They will be called after 6 months to recheck their health. If a person has a high PSA, they may be sent for more tests.

  Knowing the normal PSA level for trans women and non-binary people will help doctors to find and treat their prostate cancer more quickly.
  

• REC name

  North West - Greater Manchester South Research Ethics Committee

• REC reference

  25/NW/0176

• Date of REC Opinion

  22 Jul 2025

• REC opinion

  Further Information Favourable Opinion